Uro-Vaxom®
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Uro-Vaxom has the following effects: stimulates T-lymphocytes: induces the formation of endogenous interferon; increases the content of immunoglobulin A (IgA), including in the urine.
Uro-Vaxom reduces the frequency of recurrence of urinary tract infections, especially cystitis.
Indications
Combined treatment and prevention of recurrence of chronic urinary tract infection, especially cystitis, regardless of the nature of the microorganism, in combination with antibiotics or other antimicrobial agents in adults and children over 4 years old.
Composition
1 capsule contains:
active substance: lyophilized lysate of Escherichia coli bacteria - 6 mg;
Excipients: propyl gallate (anhydrous) - 0.084 mg; sodium glutamate (anhydrous) - 3.03 mg; mannitol to 60.00 mg; pregelatinized starch - 77.00 mg; magnesium stearate - 3.00 mg; mannitol - necessary amount up to 200.00 mg;
Auxiliary substances capsule shell: iron oxide red (E 172) - 0.01 mg; iron oxide yellow (E 172) - 0.21 mg; titanium dioxide (E 171) - 0.87 mg (dyes); gelatin to 50,00 mg
No customer reviews for the moment.
Dosage and Administration
For therapeutic purposes, prescribe 1 caps. daily in the morning on an empty stomach as an additional drug when carrying out conventional antimicrobial therapy until symptoms disappear, but not less than 10 days. The maximum duration of treatment is 3 months.
For the prevention of recurrence of chronic urinary tract infection, 1 caps is prescribed. daily in the morning on an empty stomach for 3 months.
If it is difficult for a child to swallow a capsule, it should be opened and the contents mixed with drinking (fruit juice, milk, etc.).
The duration of treatment or the appointment of a repeated course of therapy is determined individually, based on the general condition of the patient.
Adverse reactions
Individuals may experience mild gastrointestinal disturbances (diarrhea, nausea, vomiting), skin reactions (itching, exanthema, erythema), and limited allergic skin reactions. Rarely - a small fever. In the case of more severe complications, treatment should be discontinued and consult with your doctor.
Contraindications
Hypersensitivity to the drug.
Drug interactions
Interaction with other drugs has not yet been established. As a precaution, do not use the drug two weeks before and within two weeks after ingestion of live vaccines. Immunosuppressive drugs may influence the effect of the drug.
Overdosage
Information about cases of overdose are absent. The nature of the drug Uro-Vaxom and the results of the study of its toxicity indicate that overdose is unlikely.
- Brand name: Uro-Vaxom
- Active ingredient: Bacterial lysates
Studies and clinical trials of Uro-Vaxom (Click to expand)
- Administration of the bacterial extract Broncho-Vaxom® enhances radiation recovery and myelopoietic regeneration
- Upregulation of adhesion molecules induced by Broncho-Vaxom on phagocytic cells
- Radioprotective effects of WR-2721, Broncho-Vaxom® and their combinations: Survival, myelopoietic restoration and induction of colony-stimulating activity in mice
- Inhibition of spontaneous pulmonary metastases of Lewis lung carcinoma by oral treatment with Respivax and Broncho-Vaxom
- Broncho-Vaxom®inhibits histamine release from rat mast cells induced by compound 48/80 and ionophore A23187
- Adherence of Staphylococcus aureus, Klebsiella pneumoniae from healthy persons and HIV carriers, under the influence of Broncho Vaxom in vitro and ascorbic acid in vivo
- Broncho-vaxom® and spontaneous allergic autocytotoxicity (spACT) in bronchial asthma associated with food hypersensitivity
- Men's health: the bacterial extract Uro-Vaxom® protects against microbial infections of the urinary tract
- Mens Health: the bacterial extract Broncho-Vaxom® protects against influenza and Salmonella infections
- Oral Bacterial Vaccine Broncho-Vaxom Interferes Zinc Metabolism in Mononuclear Cells of Peripheral Blood of Patients With Chronic Non-Obstructive Bronchitis
- Radioprotective effects of combination broncho-vaxom, a macrophage activator, and indomethacin, an inhibitor of prostaglandin production: relationship to myelopoiesis
- Immunobiotherapy with Uro-Vaxom in Recurrent Urinary Tract Infection
- Use of Broncho-Vaxom® in private practice: Phase IV trial in 587 children
- The role of OM-85 BV (Broncho-Vaxom) in preventing recurrent acute tonsillitis in children
- Recurrent Urinary Tract Infections: Uro-Vaxom®, a New Alternative
- P788 Efficacy and safety of Uro-vaxom treatment for patients with recurrent cystitis: open multicentre study
- PUK3 ECONOMIC ASSESSMENT OF URO-VAXOM® IN FEMALE PATIENTS WITH RECURRENT URINARY TRACT INFECTION IN GERMANY
- Induction of interleukin 6 and interleukin 8 expression by Broncho-Vaxom (OM-85 BV) via C-Fos/serum responsive element.
- P225 Efficiency of Uro-Vaxom as immunoprophylaxis in patients with urogenital tract infections
- Broncho-Vaxom improves recurrent bronchitis and bronchial asthma
- Compensation of Cyclophosphamide Immunosuppression by a Bacterial Immunostimulant (Broncho-Vaxom) in Mice
- Bacterial Immunostimulant (Broncho-Vaxom) Versus Levamisole on the Humoral Immune Response in Mice